Focus: Boehringer Ingelheim is a 53,000-employee private pharmaceutical company headquartered in Germany, competing across respiratory, oncology, cardiovascular, immunology, and neuroscience with both small molecules and biologics.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Boehringer Ingelheim to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Boehringer Ingelheim
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Boehringer Ingelheim's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product representing 58% of company revenue; LOE not until 2034 provides extended runway.
Second-largest revenue generator; LOE in 2029 is a near-term patent cliff risk.
Stable DPP-4 franchise with extended exclusivity; supports diabetes portfolio depth.
Core respiratory product facing LOE in 2031; key component of $3.6B patent cliff risk.
Combination respiratory therapy; LOE in 2030 contributes to COPD portfolio erosion.
Dual-action COPD treatment; LOE in 2030 deepens respiratory market headwinds.
Extended-release combination therapy; aligns LOE date with parent JARDIANCE, supporting franchise longevity.
Anticoagulant with staggered LOE profile; declining cardiovascular franchise presence.
28 discontinued, 13 duplicate formulations not shown
+12 more products with revenue data
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent layoffs and zero active hiring signal ongoing margin pressure and function consolidation; near-term career stability risk elevated.
Recent peer-reviewed publications with author affiliations at this company
+4 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo